english

C20-OtBu-Glu(OtBu)-AEEA-AEEA-OSU

C20-OtBu-Glu(OtBu)-AEEA-AEEA-OSu is an activated pharmaceutical intermediate, characterized by its terminal N-hydroxysuccinimide (OSu) ester group. This key feature enables direct, efficient conjugation with amine-containing molecules. It is essential for the final manufacturing step of drugs like Tirzepatide and is widely used in R&D for bioconjugation, ADC development, and biomaterial functionalization, serving the advanced biopharmaceutical and life science industries.

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	C₂₀-OtBu-Glu(OtBu)-AEEA-AEEA-OSU
CAS NO.	\
Appearance	White to pale yellow amorphous powder; free-flowing, no visible aggregates.
Molecular Formula	C₄₇H₈₅N₃O₁₂
Molecular Weight	888.20 g/mol
Amino Acid Sequence	N/A (Non-peptide amino acid derivative)
Purity (RP-HPLC)	≥98.0%
Solubility	Soluble in polar organic solvents (DMSO, DMF, methanol, dichloromethane); sparingly soluble in ethanol; insoluble in water and hexane
Endotoxin	< 1.0 EU/mg
Biological Activity	This product is a self-assembling peptide intermediate and linker molecule, designed for conjugation to proteins, antibodies, or small molecules in drug development and targeted delivery systems.
Storage Conditions	Short-term (≤ 3 months): Store at 2–8°C in a cool, dry environment, protected from light and moisture. Long-term (≥ 6 months): Store at -20°C in a nitrogen-purged, airtight container to prevent hydrolysis and oxidation.
Stock Location	Stock in USA
MOQ	10g

1.MECHANISM OF ACTION

This multifunctional conjugate reagent operates through precise chemical conjugation mechanisms rather than direct biological activity. The C20 lipid chain provides strong hydrophobic interaction with cell membranes, facilitating cellular uptake and anchoring. The glutamate moiety offers an additional carboxylic acid site for further modification after deprotection. The dual AEEA PEG spacers create a hydrophilic, flexible linker that reduces steric hindrance and improves solubility of conjugated molecules.

2.PRODUCT INDICATIONS

Drug Delivery Systems – Creating lipid-PEG-drug conjugates for enhanced therapeutic delivery.

Protein/Peptide Modification – Site-specific lipidation of therapeutic proteins and peptides.

Diagnostic Agent Development – Conjugating imaging agents with improved tissue targeting.

Cell Penetration Enhancement – Improving cellular uptake of impermeable therapeutic molecules.

Nanoparticle Functionalization – Surface modification of liposomes and polymeric nanoparticles.

3.CLINICAL EFFICACY OF PRODUCT

While C20-OtBu-Glu(OtBu)-AEEA-AEEA-OSU itself is not a therapeutic agent, conjugates created using this reagent demonstrate significant clinical advantages. Lipid-PEG conjugates of therapeutic peptides show 3-5 fold increased circulation half-life compared to native peptides. Antibody-drug conjugates (ADCs) incorporating similar lipid-PEG linkers exhibit enhanced tumor penetration and reduced off-target toxicity. Imaging agents modified with these constructs demonstrate improved target-to-background ratios in diagnostic applications.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.

Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.

Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.